Eradication of vaccine-preventable diseases

Annual Review of Public Health

Volumn 20, Issue , 1999, Pages 211-229

  Hinman, A ^a  

^a Task Force for Child Survival and Development   (United States)

Author keywords

Infectious diseases; Vaccines

Indexed keywords

DIPHTHERIA VACCINE; HEPATITIS VACCINE; MEASLES VACCINE; MUMPS VACCINE; PERTUSSIS VACCINE; RUBELLA VACCINE; VACCINE;

DIPHTHERIA; HEALTH PROGRAM; HEPATITIS; HUMAN; INFECTION; MEASLES; MUMPS; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; RUBELLA; SMALLPOX; VACCINATION; WORLD HEALTH ORGANIZATION;

BACTERIAL INFECTIONS; CHILD; COMMUNICABLE DISEASE CONTROL; HUMANS; VACCINES; VIRUS DISEASES; WORLD HEALTH;

EID: 0032975522     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.20.1.211     Document Type: Review

References (62)

1. 1. Acharya AK, Murray CJL. 1998. Economic appraisal of eradication programs: the question of infinite benefits. See Ref. 30, pp. 75-90
2. 2. Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. 1998. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenza type b among Gambian children. J. Infect. Dis. 177:1758-61
3. 3. Aylward RB, Olivé J-M, Hull HF, de Quadros CA, Melgaard B. 1998. Disease eradication initiatives and general health services: ensuring common principles lead to mutual benefits. See Ref. 30, pp. 61-74
4. 4. Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. 1998. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg. Infect. Dis. 4:1-12
5. 5. Cent. Dis. Control Prev. 1991. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures; recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly. Rep. 40(RR-10):1-28
6. 6. Cent. Dis. Control Prev. 1991. Rabies prevention-United States, 1991: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly. Rep. 40(RR-3):1-19
7. 7. Cent. Dis. Control Prev. 1993. Inactivated Japanese encephalitis virus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly. Rep. 42(RR-I):1-15
8. 8. Cent. Dis. Control Prev. 1993. Recommendations of the International Task Force for Disease Eradication. Morbid. Mortal. Wkly. Rep. 42(RR-16):1-38
9. 9. Cent. Dis. Control Prev. 1994. Typhoid immunization: recommendations of the Advisory Committee on Immunization Practices. Morbid. Mortal. Wkly. Rep. 43(RR-14):1-7
10. 10. Cent. Dis. Control Prev. 1996. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly. Rep. 45(RR-15):1-30
11. 11. Cent. Dis. Control Prev. 1996. Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly. Rep. 45(RR-14):1-15
12. 12. Cent. Dis. Control Prev. 1996. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly. Rep. 45(RR-H):1-36
13. 13. Cent. Dis. Control Prev. 1997. Control and prevention of meningococcal disease and control and prevention of serogroup C menigococcal disease: evaluation and management of suspected outbreaks; recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly. Rep. 46(RR-5):1-21
14. 14. Cent. Dis. Control Prev. 1997. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. Morbid. Mortal. Wkly. Rep. 46(RR-11):1-21
15. 15. Cent. Dis. Control Prev. 1997. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children; recommendations of the Advisory Committee on Immunization Practices. Morbid. Mortal. Wkly. Rep. 46(RR-7):1-25
16. 16. Cent. Dis. Control Prev. 1997. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal Wkly. Rep. 46(RR-3):1-25
17. 17. Cent. Dis. Control Prev. 1997. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly. Rep. 46(RR-8):1-24
18. 18. Cent. Dis. Control Prev. 1998. Progress toward global eradication of poliomyelitis, 1997. Morbid. Mortal. Wkly. Rep. 47:414-19
19. 19. Cent. Dis. Control Prev. 1998. Advances in global measles control: summary of the 1997 international meeting. Morbid. Mortal. Wkly. Rep. 47(RR-11):1-23
20. 20. Cent. Dis. Control Prev. 1998. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly. Rep. 47(RR-8):1-57
21. 21. Cent. Dis. Control Prev. 1998. Measles -United States, 1997. Morbid. Mortal. Wkly. Rep. 47:273-76
22. 22. Cent. Dis. Control Prev. 1998. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly. Rep. 47(RR-6):1-26
23. 23. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 271:698-702
24. 24. Cutts FT, Robertson SE, Diaz-Ortega JL, Samuel R. 1997. Control of rubella and congenital rubella syndrome (CRS) in developing countries: part 1. burden of disease from CRS. Bull. WHO 75:55-68
25. 25. Cutts FT, Steinglass R. 1998. Should measles be eradicated? Br. Med. J. 316:1-7
26. 26. de Quadros CA, Hersh BS, Nogueira AC, Carrasco PA, da Silveria CM. 1998. Measles eradication: experience in the Americas. See Ref. 34, pp. 47-52
27. 27. Deville JG, Cherry JD, Christenson PD, Pineda E, Leach CT, et al. 1995. Frequency of unrecognized Bordetella pertussis infections in adults. Clin. Infect. Dis. 21:639-42
28. 28. Dittmann S, Ciotti M. 1997. Epidemic diphtheria in the Newly Independent States and the Baltic countries: document CMDS070103/8. Copenhagen: WHO Reg. Off. Eur.
29. 29. Dove AW, Racaniello VR. 1997. The polio eradication effort: Should vaccine eradication be next? Science 277:779-80
30. 30. Dowdle WR, Hopkins DR, eds. 1998. The Eradication of Infectious Diseases. New York: Wiley. 218 pp.
31. 31. Fenner F, Henderson DA, Arita I, Jezek A, Ladnyi ID. 1988. Smallpox and Its Eradication. Geneva: WHO.
32. 32. Foege WH. 1998. Synthesis of conference and vision for the future. See Ref. 34, pp. 109-12
33. 33. Galazka AM, Robertson SE, Oblapenko GP. 1995. Resurgence of diphtheria. Eur. J. Epidemiol. 11:95-105
34. 34. Goodman RA, Foster KL, Trowbridge FL, Figueroa JP, eds. Global Disease Elimination and Eradication as Public Health Strategies. Proceedings of a conference in Atlanta, GA: Feb. 23-25, 1998. Bull WHO 76 (suppl.2):1-162
35. 35. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, et al. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:341-48
36. 36. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. 1996. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:349-55
37. 37. Gyldmark M, Alban A. 1998. An economic perspective on programs proposed for eradication of infectious diseases. See Ref. 30, pp. 91-104
38. 38. Hall RG, Acharya AK, Aylward RB, Gyldmark M, Hall AJ, et al. 1998. Group report: What are the criteria for estimating the costs and benefits of disease eradication? See Ref. 30, pp. 107-16
39. 39. Hinman AR. 1998. Report of the Bacterial Diseases Workgroup. See Ref. 34, pp. 85-88
40. 40. Hinman AR, Bart KJ, Orenstein WA, Preblud SR. 1983. Rational strategy for rubella vaccination. Lancet 1:39-41
41. 41. Hinman AR, Foege WH, de Quadros CA, Patriarca PS, Orenstein WA, Brink EW. 1987. The case for global eradication of poliomyelitis. Bull. WHO 65:835-40
42. 42. Hopkins DR, Hinman AR, Koplan JP, Lane JM. 1992. The case for global measles eradication. Lancet 1:1396-98
43. 43. Hull HF, Aylward RB. 1997. Ending polio immunization. Science 277:780
44. 44. Hull HF, 1997. Pax polio. Science 275:40-41
45. 45. Losos J. 1998. Report of the Viral Diseases Workgroup. See Ref. 34, pp. 94-102
46. 46. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, et al, 1997. Randomized trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 349:1191-97
47. 47. Orenstein WA, Bart KJ, Hinman AR, Preblud SR, Greaves WL, et al. 1984. The opportunity and obligation to eliminate rubella from the United States. JAMA 251:1988-94
48. 48. Ottesen EA, Dowdle WR, Fenner F, Habermehl K-O, John TJ, et al. 1998. Group report: How is eradication to be defined and what are the biological criteria? See Ref. 30, pp. 47-59
49. 49. Pan American Health Organization. 1997. SV1 technical advisory group meets. EPI Newsl. 19:1-4
50. 50. Pan American Health Organization. 1995. The impact of the Expanded Program on Immunization and the Polio Eradication Initiative on health systems in the Americas: Final Report of the "Taylor Commission." Washington, DC: PAHO. 82 pp.
51. 51. Robbins JB, Schneerson R, Anderson P, Smith DH. 1996. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b: impact on public health and implications for other polysaccharide-based vaccines. JAMA 276:1181-85
52. 52. Robertson SE, Cutts FT, Samuel R, Diaz-Ortega J-L. 1997. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 2: vaccination against rubella. Bull. WHO 75:69-80
53. 53. Rodrigues LC, Diwan VK, Wheeler JG. 1993. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. 22:1154-58
54. 54. Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Uberall M, et al. 1998. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DtaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 101:1-11
55. 55. Stuart-Harris C, Western KA, Chamberlayne EC, eds. 1982. Can infectious diseases be eradicated? A report on the International Conference on the Eradication of Infectious Diseases. Rev. Infect. Dis. 4:913-84
56. 56. Sutter R, Cochi S. 1997. Comment: ethical dilemmas in worldwide polio eradication programs. Am. J. Public Health 87:913-15
57. 57. Taylor CE, Cutts F, Taylor ME. 1997. Ethical dilemmas in current planning for polio eradication. Am. J. Public Health 87:922-25
58. 58. Taylor CE, Waldman RJ. 1998. Designing eradication programs to strengthen primary health care. See Ref. 30, pp. 145-55
59. 59. World Health Organization. 1988. Global eradication of poliomyelitis by the year 2000. World Health Assembly Res. WHA4I.28
60. 60. World Health Organization. 1996. State of the World's Vaccines and Immunization. Geneva: WHO. 161 pp.
61. 61. World Health Organization. 1997. The World Health Report 1997: Conquering Suffering, Enriching Humanity. Geneva: WHO. 162 pp.
62. 62. Wright PF, Kim-Farley RJ, de Quadros CA, Robertson SE, Scott RMcN, et al. 1991. Strategies for the global eradication of poliomyelitis by the year 2000. N. Engl. J. Med. 325:1774-79